If you have been reading about preclinical research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-29. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
== Interactions == Phenibut may mutually potentiate and extend the duration of the effects of other CNS depressants, including anxiolytics, antipsychotics, sedatives, opioids, anticonvulsants, and alcohol.
=== Other Pacific nations === Several governments of Pacific nations, including Samoa, Fiji, Vanuatu, and Papua New Guinea, publicly reported by the end of March that they had enough fuel reserves to continue operating for a few months. However, some officials have privately expressed concerns about the future if oil deliveries to the region are halted owing to the war, and prices have gone up in all of these countries as well as Solomon Islands, Tonga, and Marshall Islands. Officials in Samoa, Cook Islands and Fiji have warned citizens against panic buying and hoarding. Australian Foreign Minister Penny Wong and Minister for Pacific Island Affairs Pat Conroy have signalled their willingness to ensure that regional neighbours do not run out of fuel. The New Zealand Government stated that it was assessing how it could help the Pacific region, particularly the Polynesian nations. Due to rising fuel costs, Air New Zealand has cancelled 1,100 flights in the Pacific region, affecting around 44,000 passengers.
Their diet in the wild primarily consists of dark green vegetables such as grasses and clovers, and excessive carrot consumption is unhealthy for them due to containing high levels of sugar. Tomato juice and sauce are ineffective at neutralizing the odor of a skunk. Rather, due to olfactory fatigue, a person sprayed by a skunk loses sensitivity to the smell over time. Effective treatments for skunk odor involve artificial compounds rather than household remedies. There is no such thing as an "alpha" in a wolf pack. An early study that coined the term "alpha wolf" had observed only unrelated adult wolves living in captivity. In the wild, wolf packs operate like families: parents are in charge until the young grow up and start their own families, and younger wolves do not overthrow an "alpha" to become the new leader. The phases of the Moon have no effect on the vocalizations of wolves, and wolves do not howl at the Moon. Wolves howl to assemble the pack usually before and after hunts, to pass on an alarm particularly at a den site, to locate each other during a storm, while crossing unfamiliar territory, and to communicate across great distances.
=== Lawsuits === From 2019 to 2024, Maria Francesca Gioia, a former medical student acting as a pro se plaintiff, filed nine product liability lawsuits against Janssen Pharmaceuticals and related parties. She alleged that taking Invega Sustenna (paliperidone palmitate) caused her memory loss, hypothyroidism, Horner's syndrome, nerve damage, motor tremors, vocal tics, confusion, loss of taste and sensation, post-traumatic stress disorder, and metabolic syndrome (including hypertension, diabetes, and stroke), which ended her career as a primary care physician. All nine lawsuits were dismissed on procedural grounds: Gioia I–II for failure to state a claim, Gioia III for failure to prosecute, and Gioia IV–V for lack of subject matter jurisdiction. The court also noted that the side effects she alleged were already listed on Invega's FDA-approved warning label. In June 2020, a Florida lawsuit was filed on behalf of Lilith Geohaghan, an 82-year-old assisted living resident with Lewy body dementia, against the assisted living facility and several healthcare providers. The complaint alleged that despite her family's explicit instructions to the contrary, she was administered multiple large doses of Invega Sustenna in late 2018. The lawsuit claims that the injections led to a rapid decline in her health, resulting in nearly a dozen falls and two hospitalizations within just over a month. Her treating physicians subsequently diagnosed her with toxic encephalopathy, directly attributing the condition to the Invega Sustenna injections.
== Mechanism of action == The MeCP2 protein binds to forms of DNA that have been methylated. The MeCP2 protein then interacts with other proteins to form a complex that turns off the gene. MeCP2 prefers to bind to sites on the genome with a chemical alteration made to a cytosine (C) when it occurs in a particular DNA sequence, "CpG". This is a form of DNA methylation. Many genes have CpG islands, which frequently occur near the beginning of the gene. MECP2 does not bind to these islands in most cases, as they are not methylated. The expression of a few genes may be regulated through methylation of their CpG island, and MECP2 may play a role in a subset of these. Researchers have not yet determined which genes are targeted by the MeCP2 protein, but such genes are probably important for the normal function of the central nervous system. However, the first large-scale mapping of MECP2 binding sites in neurons found that only 6% of the binding sites are in CpG islands, and that 63% of MECP2-bound promoters are actively expressed and only 6% are highly methylated, indicating that MECP2's main function is something other than silencing methylated promoters. Once bound, MeCP2 will condense the chromatin structure, form a complex with histone deacetylases (HDAC), or block transcription factors directly. More recent studies have demonstrated that MeCP2 may also function as a transcriptional activator, through recruiting the transcription factor CREB1.
Sources: en.wikipedia.org
** not really an RTG, the BES-5 Buk (БЭС-5) reactor was a fast reactor which used thermocouples based on semiconductors to convert heat directly into electricity *** not really an RTG, the SNAP-10A used enriched uranium fuel, zirconium hydride as a moderator, liquid sodium potassium alloy coolant, and was activated or deactivated with beryllium reflectors Reactor heat fed a thermoelectric conversion system for electrical production. **** not really an RTG, the ASRG uses a Stirling power device that runs on radioisotope (see Stirling radioisotope generator)
For example, RasGTP signals link with the mitogen activated protein kinase (MAPK) cascade to amplify the allosteric activation of proliferative transcription factors such as Myc and CREB. Earl Wilbur Sutherland Jr., discovered second messengers, for which he won the 1971 Nobel Prize in Physiology or Medicine. Sutherland saw that epinephrine would stimulate the liver to convert glycogen to glucose (sugar) in liver cells, but epinephrine alone would not convert glycogen to glucose. He found that epinephrine had to trigger a second messenger, cyclic AMP, for the liver to convert glycogen to glucose. The mechanisms were worked out in detail by Martin Rodbell and Alfred G. Gilman, who won the 1994 Nobel Prize. Secondary messenger systems can be synthesized and activated by enzymes, for example, the cyclases that synthesize cyclic nucleotides, or by opening of ion channels to allow influx of metal ions, for example Ca2+ signaling. These small molecules bind and activate protein kinases, ion channels, and other proteins, thus continuing the signaling cascade.
1. FC Lokomotive Leipzig has undergone several reorganizations during its history and has taken several different forms and names. The club was a football department of sports clubs SC Rotation Leipzig and later SC Leipzig, before being reorganized as football club 1. FC Lokomotive Leipzig in 1966.
Pyrite is usually found associated with other sulfides or oxides in quartz veins, sedimentary rock, and metamorphic rock, as well as in coal beds and as a replacement mineral in fossils, but has also been identified in the sclerites of scaly-foot gastropods. Despite being nicknamed "fool's gold", pyrite is sometimes found in association with small quantities of actual gold. A substantial proportion of this is "invisible gold" incorporated into the pyrite. It has been suggested that the presence of both gold and arsenic is a case of coupled substitution. However, as of 1997, the chemical state of the gold remained controversial.
For instance, both mammals and birds lack the same 14 out of the possible 64 tRNA genes, but other life forms contain these tRNAs. For translating codons for which an exactly pairing tRNA is missing, organisms resort to a strategy called wobbling, in which imperfectly matched tRNA/mRNA pairs still give rise to translation, although this strategy also increases the propensity for translation errors. The reasons why tRNA genes have been lost during evolution remains under debate but may relate improving resistance to viral infection. Because nucleotide triplets can present more combinations than there are amino acids and associated tRNAs, there is redundancy in the genetic code, and several different 3-nucleotide codons can express the same amino acid. This codon bias is what necessitates codon optimization.
Sources: en.wikipedia.org
== Texas House of Representatives == Talarico was first elected to the Texas House of Representatives in 2018 at age 29, becoming the legislature's youngest member during the 2019 session. During his four terms in the Republican-majority legislature, Talarico served as lead author of nearly 200 bills, 16 of which became law. Eight of the enacted bills addressed education, childcare, or youth workforce development.
1% (w/w) Nonidet P-40 (NP-40) 1% (w/v) sodium deoxycholate 0.1% (w/v) SDS 0.15 M NaCl 0.01 M sodium phosphate, pH 7.2 2 mM EDTA 50 mM sodium fluoride (NaF) 0.2 mM fresh sodium orthovanadate (Na3VO4.2H2O, it has phosphatase inhibitor function because it mimics phosphate) 100 U/ml protease inhibitor, such as aprotinin
=== Clinical presentation === Rabson and Mendenhall described three siblings (2 girls, 1 boy) who initially presented with dental and skin abnormalities, abdominal distention, and phallic enlargement. The children demonstrated early dentition, a coarse, senile-appearing facies, and striking hirsutism. An "adult growth of hair of head" at 5 years of age was pictured in the case of one of the girls. In the older girl, the genitalia were large enough at the age of 6 months to permit vaginal examination for diagnosis of a left ovarian tumor which was removed soon afterward. The children were mentally precocious. Prognathism and very thick fingernails as well as acanthosis nigricans were also described. Insulin-resistant diabetes developed, and the patients died during childhood of ketoacidosis and intercurrent infections. At autopsy pineal hyperplasia was found in all three. Biologically, infants display fasting hypoglycemia, postprandial hyperglycemia and hyperinsulinemia, which progress to permanent hyperglycemia and recurrent diabetic ketoacidosis.
A record in the form of proof of baptisms shall be made, containing the time and hour of birth. An extract from this register may be used to prove the age of majority or minority and will serve as full legal evidence for this purpose. Before this legal requirement, fifteen Parisian parishes already kept baptismal registers, three kept marriage registers, and one kept burial registers. Presided over by Pope Paul III from 1545 to 1563, the Council of Trent also required priests to keep a register of baptisms performed in their parish. The names of godparents had to be included to prevent marriages between people linked by spiritual kinship (e.g., a godfather and his goddaughter could not marry). The council also mandated that marriages, freely contracted before a priest and two or three witnesses, be preceded by the publication of banns and recorded in a designated register. It also advocated for the union of children without requiring parental consent. In May 1579, the Ordinance of Blois extended the obligation to keep marriage and burial registers throughout France. The Ordinance of Saint-Germain-en-Laye of April 1667, known as the "Code Louis," required these registers to be kept in duplicate: the first copy (the minute) remained in the parish, while the duplicate (the grosse) was deposited at the court registry. In Paris, the Châtelet registry preserved the second copy, with the oldest dating back to 1668. By 1790, the capital had around fifty parishes.
A comparative genomic study (in 2020) analyzed 494 complete genomes from the Pseudomonas genus, of which 189 were P. aeruginosa strains. The study observed that their protein count and GC content ranged between 5500 and 7352 (average: 6192) and between 65.6 and 66.9% (average: 66.1%), respectively. This comparative analysis further identified 1811 aeruginosa-core proteins, which accounts for more than 30% of the proteome. The higher percentage of aeruginosa-core proteins in this latter analysis could partly be attributed to the use of complete genomes. Although P. aeruginosa is a very well-defined monophyletic species, phylogenomically and in terms of ANIm values, it is surprisingly diverse in terms of protein content, thus revealing a very dynamic accessory proteome, in accordance with several analyses. It appears that, on average, industrial strains have the largest genomes, followed by environmental strains, and then clinical isolates. The same comparative study (494 Pseudomonas strains, of which 189 are P. aeruginosa) identified that 41 of the 1811 P. aeruginosa core proteins were present only in this species and not in any other member of the genus, with 26 (of the 41) being annotated as hypothetical. Furthermore, another 19 orthologous protein groups are present in at least 188/189 P. aeruginosa strains and absent in all the other strains of the genus.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.